[1] 曹彬,丰义宽,李国庆. 肝硬化患者小肠细菌过度生长与轻微肝性脑病发生的相关性研究. 实用肝脏病杂志,2008,11(1):50-52. [2] Chang CS,Chen GH,Lien HC,et al. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology,1998,28(5):1187-1190. [3] Bures J,Cyrany J,Kohoutova D,et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol,2010,16(24):2978-2990. [4] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南. 实用肝脏病杂志,2011,14(2):81-89. [5] Pande CA,Kumar SK. Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease. Aliment Pharmacol Ther,2009. 29(12):1273-1281. [6] Lombardo L,Foti M,Ruggia O,et al. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol,2010,8(6):504-508. [7] Jacobs C,Coss Adame E,Attaluri A,et.al. Dysmotility and proton pump inhibitor use are independent risk factor for small intestinal bacterial and/or fungal overgrowth.Aliment Pharmacol Ther 2013,37:1103-1111. [8] Pardo A,Bartoli R,Lorenzo-Zuniga V,et al. Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis. Hepatology,2000,31(4):858-863. [9] 逢作祥,李晓东,吕小军,等. 小肠细菌过度生长与肝硬化的关系探讨. 实用肝脏病杂志,2008,11(5):327-328. [10] 周红宇,周国华,冷明芳,等. 肝硬化小肠细菌过度生长情况分析.疑难病杂志,2011,10(3):185-187. [11] Morencos FC,delas Heras Castano G,Martin Ramos L,et al. Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci,1995,40:1252-1256. [12] Yang CY,Chang CS,Chen GH. Small-intestinal bacterial overgrowth in patients with liver cirrhosis,diagnosed with glucose H2 or CH4 breath tests. Scand J Gastroenterol,1998,33:867-871. [13] Wilberg S,Pieramico 0,Malfertheiner P.The H2-lactulose breath test in the diagnosis of intestinal transittime.Leber Magen Darm,1990,20(3):129-137. [14] Chen CY,Lu CL,Chang FY,et a1.Delayed gastrointestinal transit in patients with hepatocellular carcinoma.J Gastroenterol Hepatol,2002,17(12):1254-1269. [15] 曹曙光,吴昊,徐昌隆,等. 肝硬化患者小肠细菌过度生长在肠道气体产生中的作用. 中华肝脏病杂志,2010,18(11):864-865. [16] 李山林,刘学进,周洪涛. 肝硬化与小肠细菌过度生长的关系.中国当代医药,2014,21(35):58-60. [17] Morgenthaler NG,Struck J,Chancerelle Y,et a1.Production of procalcitonin(PCT)in non-thyroidal tissue after LPS injection.Horm Metab Res,2003,35(5):290-295. [18] The Organize of the Expert Consensus on the Clinical Application of Procalcitonin in Emergency.The expert consensus on the clinical application of procalcitonin in emergency.Chin J Emerg Med,2012,21(9):944-951. [19] Bota DP,Van Nuffelen M,Zakariah AN,et a1.Serum levels of C-reactive protein and procalcitonin in critically ill patients with cirrhosis of the liver.J Lab C1iIl Med,2005,146(6):347-351. [20] Lesinska M,Hartleb M,Gutkowski K,et a1.Procalcitonin and macrophage inflammatory protein-1 beta(MIP-1β)in serum and peritoneal fluid of patients with decompensated cirrhosis and spontaneous bacterial peritonitis.Adv Med Sci,2014,59(1):52-56. [21] Connert S,Stremmel W,Elsing C.Procalcitonin is a valid marker of infection in decompensated cirrhosis.Z Gastroenterol,2003,4l(2):165-170.